Context

This dataset is a capitation list containing the list of staff of a company eligible for treatment for the specified period of time. With this dataset, One can study how much a company spends on her staff on a monthly basis, how often staffs are added to the health insurance scheme and how often staffs are withdrawn from the scheme.

Content

The datasets contains the following column with about 103385 rows which is the data of two months 2017-09-01 and 2017-10-01

• ID_capitation
• Hospital_ID
• CapitationAmount
• ValueDate
• CompanyID
• PatientUniqueID
• CapitationType

Inspiration

How can we eradicate fraud from this system because capitation Fee are still being paid on some ghost staffs.

About this Dataset

**Business to Consumer TCPA Compliant Leads You can use this leads for DME medicare A or B, Medicare Advantage and Med Supplement **Which industry is your product used for:Medicare AdvantageMed SuppDME-Med-BPharmaceutical SalesPPO / HMO/ MED BPain CreamDME-PPO (Durable Medical Equipment) **Information included on the leads Contacts name Contacts phone number (DNC scrubbed)

Email

These leads are low-income, in the best Dual Advantage areas in the US! These leads are a steal, I am selling these leads at a very reasonable price. I am sure that you will have benefits buying these products and will be back for more leads! Buy leads with amazing results! Leads are generated through client looking for a better health insurance plan and currently on Medicare Parts A and B. They opt-in or fill out a form on my websites Best TCPA leads you will find on the market right now. Med A and B leads looking for better health insurance plans and DME

Which industry is your product used for:Diabetic Supply DME Catheters DME Tele-Med DME Wheelchairs DME-HMO DME-Med-B DME-Posted DME-PPO (Durable Medical Equipment) Durable Medical Equipment (DME) Health Insurance Medical Devices Lead Generation Medicare Supplement Pain Cream TCPA Compliant Leads Best TCPA leads you will find on the market right now. Med A and B leads looking for better health insurance plans and DME What type of volume can you do per day? 10000 Aged Sales Leads A Day Describe in detail how your product is generated and sent over: Leads are generated through client looking for a better health insurance plan and currently on Medicare Parts A and B. They opt-in or fill out a form on my websites Why should someone pick your product? Best TCPA leads you will find on the market right now. Med A and B leads looking for better health insurance plans and DME Is your Data TCPA Compliant? Yes Once you accept an offer how soon can you start? ASAP how do i charge? Per Lead

Category

Health & Medicine

Keywords

health insurance,insurance,Email List,Email Leads,US Data

Row Count

24595

Price

$3000.00

Human Milk Oligosaccharides (HMO) Market Outlook

According to our latest research, the global Human Milk Oligosaccharides (HMO) market size reached USD 267.3 million in 2024, driven by rising consumer awareness of infant nutrition and advances in biotechnology. The market is expanding at a robust CAGR of 22.8% and is projected to reach USD 2.1 billion by 2033. This substantial growth is attributed to the increasing demand for infant formula fortified with HMOs, growing investments in research and development, and a surge in health-conscious consumers seeking functional foods and supplements. As per our latest research, the HMO market is experiencing a paradigm shift as manufacturers and consumers alike recognize the critical role of HMOs in supporting immune function and gut health, particularly in infants and young children.

One of the primary growth factors propelling the Human Milk Oligosaccharides market is the increasing prevalence of infant malnutrition and the corresponding demand for advanced infant nutrition solutions. As global birth rates remain steady and more parents seek optimal alternatives to breast milk due to lifestyle or medical reasons, the demand for infant formula fortified with HMOs has surged. HMOs are recognized for their prebiotic benefits and ability to mimic the composition and functionality of human breast milk, providing infants with enhanced immune protection and improved digestive health. Furthermore, the World Health Organization’s recommendations on exclusive breastfeeding for the first six months have indirectly driven innovation in infant formula, with manufacturers striving to bridge the nutritional gap through the addition of HMOs. This trend is reinforced by clinical studies demonstrating the positive impact of HMOs on infant growth and development, fostering increased adoption among parents and healthcare providers.

Another significant factor fueling market expansion is the rapid advancement in biotechnological processes that enable the large-scale, cost-effective production of HMOs. Traditionally, the extraction of HMOs from human milk was not feasible for commercial purposes; however, the development of enzymatic and microbial fermentation techniques has revolutionized the industry. These innovations have made it possible to produce a variety of HMOs, such as 2’-fucosyllactose (2’-FL) and lacto-N-neotetraose (LNnT), in sufficient quantities to meet growing demand. The scalability and purity of synthetic and enzymatic HMOs have attracted major investments from both established nutrition companies and biotechnology startups. This technological leap has also facilitated regulatory approvals in key markets, further accelerating the commercialization and integration of HMOs into a wide range of food and pharmaceutical products.

The evolving consumer landscape, characterized by a heightened focus on preventive healthcare and functional nutrition, is another pivotal driver of the HMO market. Parents and health-conscious individuals are increasingly seeking products that support not only basic nutrition but also long-term health outcomes, such as immune resilience and gut microbiome balance. HMOs, with their scientifically validated benefits, are being incorporated into functional foods, beverages, and dietary supplements beyond infant formula. This diversification is expanding the addressable market for HMOs, attracting new consumer segments and fostering collaborations between food, beverage, and pharmaceutical companies. The convergence of consumer demand, scientific validation, and product innovation is expected to sustain the momentum of the HMO market well into the next decade.

From a regional perspective, the Human Milk Oligosaccharides market demonstrates significant growth potential across both developed and emerging economies. North America and Europe are leading the adoption curve, supported by advanced healthcare infrastructure, high levels of consumer awareness, and favorable regulatory environments. Meanwhile, the Asia Pacific region is emerging as a lucrative market, driven by rising birth rates, increasing disposable incomes, and a growing middle class that is willing to invest in premium infant nutrition products. The expansion of e-commerce platforms and the proliferation of specialty stores are further facilitating market penetration in these regions. As multinational companies expand their footprint and local players innovate to meet regional preferences, the global HMO market is poised for sustained and geographically diversif

This page, "HMo", is part of the NIST Chemistry WebBook. This site and its contents are part of the NIST Standard Reference Data Program.

This is a dataset of properties deemed to be a House of Multiple Occupation (HMO), or shared occupation as used by the council's Planning section as an evidence base for future HMO applications. The data is sourced from council tax data and is solely used by the council for planning use and is not intended to represent a definitive list of HMOs in the city.

Code descriptions

• N = Property solely occupied by full time students
• M = Halls of residence (property can only be occupied by students)
• OL = A dwelling inhabited by persons who do not constitute a single household where the owner is liable for council tax (HMO)

Human Milk Oligosaccharide Fortified Formula Sachet Market Outlook

According to our latest research, the global Human Milk Oligosaccharide (HMO) Fortified Formula Sachet market size reached USD 1.56 billion in 2024, reflecting the rapid adoption of HMO-fortified products across pediatric and infant nutrition segments. The market is projected to grow at a robust CAGR of 13.2% from 2025 to 2033, reaching a forecasted value of USD 4.20 billion by 2033. This impressive growth is primarily attributed to increasing awareness of the health benefits associated with HMOs, advancements in infant formula technology, and a rising demand for convenient, sachet-based nutritional solutions tailored for infants and young children.

The primary growth factor driving the Human Milk Oligosaccharide Fortified Formula Sachet market is the mounting body of scientific evidence supporting the role of HMOs in promoting gut health, immune function, and cognitive development in infants. HMOs, such as 2’-Fucosyllactose (2’-FL), 3’-Fucosyllactose (3’-FL), and Lacto-N-neotetraose (LNnT), are unique prebiotic compounds naturally found in human breast milk. Their incorporation into formula sachets is revolutionizing the infant nutrition sector, enabling formula-fed infants to benefit from nutrients previously exclusive to breastfed babies. As parents become increasingly informed about the importance of early-life nutrition and the microbiome, demand for HMO-fortified formula sachets has surged, particularly in markets with high rates of formula feeding.

Another significant driver is the innovation in packaging formats, particularly the shift toward single-serve sachets. Sachet packaging offers unparalleled convenience, ensuring precise dosage, longer shelf life, and easy portability for caregivers. This trend has been further accelerated by the rise of dual-income households and urbanization, where parents seek practical, on-the-go nutrition solutions for their children. The sachet format also minimizes the risk of contamination, enhances product stability, and aligns with the growing preference for hygienic, ready-to-use nutritional products. Manufacturers are leveraging these benefits to penetrate emerging markets, where affordability and accessibility remain critical factors.

Furthermore, the expansion of distribution networks through online stores, supermarkets, hypermarkets, and pharmacies has significantly broadened the reach of HMO-fortified formula sachets. Digital transformation in the retail sector, coupled with strategic partnerships between manufacturers and healthcare providers, has facilitated greater consumer access and education. Regulatory approvals for the use of HMOs in infant nutrition across key regions such as North America, Europe, and Asia Pacific have also played a pivotal role in market expansion. These factors, combined with ongoing research into the diverse applications of HMOs beyond infant nutrition, are expected to sustain the market’s upward trajectory throughout the forecast period.

Regionally, North America and Europe currently dominate the Human Milk Oligosaccharide Fortified Formula Sachet market, accounting for a substantial share of global revenue. However, the Asia Pacific region is emerging as the fastest-growing market due to rising birth rates, increasing health consciousness among parents, and improving healthcare infrastructure. Latin America and the Middle East & Africa are also witnessing steady growth, driven by urbanization and expanding middle-class populations. As global awareness of HMO benefits continues to rise, these regions are expected to play an increasingly important role in shaping the future landscape of the market.

Product Type Analysis

The Human Milk Oligosaccharide Fortified Formula Sachet market is segmented by product type into 2’-FL Fortified, 3’-FL Fortified, LNnT Fortified, and Others. Among these, 2’-FL Fortified sachets hold the largest market shar

Human milk oligosaccharides (HMOs) have attracted much attention in recent years not only as a prebiotic factor but also in particular as an essential component of infant nutrition in relation to their impact on innate immunity. The backbone structures of complex HMOs generally contain single or repetitive lacto-N-biose (type 1) or lactosamine (type 2) units in either linear or branched chains extending from a lactose core. While all known branched structures originate from the 3,6-substitution of the lactosyl core galactose, we here describe a new class of HMOs that tentatively branch at the terminal galactose of 6′-galactosyllactose. Another novel feature of this class of HMOs was found in linear oligo-galactosyl chains linked to one of the N-acetylglucosamine (GlcNAc) branches. The novel structures exhibit general formulas with hexose versus hexosamine contents of 5/2 to 8/2 and can be designated as high-galactose (HG)-HMOs. In addition, up to three fucosyl residues are linked to the octa- to dodecasaccharides, which were detected in two human milk samples from the Lewis blood-group-defined donors. Structural analyses of methylated glycans and their alditols comprised matrix-assisted laser desorption ionization mass spectrometry, electrospray-(collision-induced dissociation) mass spectrometry and linkage analyses by gas chromatography–mass spectrometry of the derived partially methylated alditol acetates. Enzymatic degradation by the application of β1–3,4-specific galactosidase supported the presence of terminal galactose-linked β1–6 to one of the two GlcNAc branches. The mass spectrometry glycomic data have been deposited at the GlycoPOST archive with the data set identifier GPST000191 (Username: franz.hanisch@uni-koeln.de; Password: Soma1Dita2Carb. Watanabe, Y. GlycoPOST realizes FAIR principles for glycomics mass spectrometry data. Nucleic Acids Res. 2021, 49, D1523–D1528)

BackgroundHuman milk oligosaccharides (HMOs) have important biological functions for a healthy development in early life.ObjectiveThis study aimed to investigate gut maturation effects of an infant formula containing five HMOs (2′-fucosyllactose, 2′,3-di-fucosyllactose, lacto-N-tetraose, 3′-sialyllactose, and 6′-sialyllactose).MethodsIn a multicenter study, healthy infants (7–21 days old) were randomly assigned to a standard cow’s milk-based infant formula (control group, CG); the same formula with 1.5 g/L HMOs (test group 1, TG1); or with 2.5 g/L HMOs (test group 2, TG2). A human milk-fed group (HMG) was enrolled as a reference. Fecal samples collected at baseline (n∼150/formula group; HMG n = 60), age 3 (n∼140/formula group; HMG n = 65) and 6 (n∼115/formula group; HMG n = 60) months were analyzed for microbiome (shotgun metagenomics), metabolism, and biomarkers.ResultsAt both post-baseline visits, weighted UniFrac analysis indicated different microbiota compositions in the two test groups (TGs) compared to CG (P < 0.01) with coordinates closer to that of HMG. The relative abundance of Bifidobacterium longum subsp. infantis (B. infantis) was higher in TGs vs. CG (P < 0.05; except at 6 months: TG2 vs. CG P = 0.083). Bifidobacterium abundance was higher by ∼45% in TGs vs. CG at 6-month approaching HMG. At both post-baseline visits, toxigenic Clostridioides difficile abundance was 75–85% lower in TGs vs. CG (P < 0.05) and comparable with HMG. Fecal pH was significantly lower in TGs vs. CG, and the overall organic acid profile was different in TGs vs. CG, approaching HMG. At 3 months, TGs (vs. CG) had higher secretory immunoglobulin A (sIgA) and lower alpha-1-antitrypsin (P < 0.05). At 6 months, sIgA in TG2 vs. CG remained higher (P < 0.05), and calprotectin was lower in TG1 (P < 0.05) vs. CG.ConclusionInfant formula with a specific blend of five HMOs supports the development of the intestinal immune system and gut barrier function and shifts the gut microbiome closer to that of breastfed infants with higher bifidobacteria, particularly B. infantis, and lower toxigenic Clostridioides difficile.Clinical Trial Registration[https://clinicaltrials.gov/ct2/show/], identifier [NCT03722550].

The Housing in Multiple Occupation (HMO) licence register shows if a landlord has been issued with a HMO licence for his/her property and the expiry date of the licence.

New licence applications will not appear on the register until they have been processed and issued. Landlords of properties issued with HMO licences must display a copy of their licence in a prominent position in the licensed premises.

It is an offence for a person to have control of, or manage a licensable HMO without a licence or without applying for a licence. If you are a managing agent DO NOT engage in any business activity with an unlicensed landlord. You may be committing an offence and could face prosecution.

Contact us

• If you have any queries in relation to a property which has been licensed, or which you feel should be licensed, please contact the HMO Licensing Team on 0113 3784698 or email: HMO.Team@leeds.gov.uk.
• Can we make this dataset even better? What's useful to you? Get in touch with us at open.data@leeds.gov.uk - we'd love to hear from you!

In this study, we quantitated the disappearance of intact HMOs and characterized the glycan digestion products in the gut that are produced by the action of microbial enzymes on HMOs and glycoconjugates from breast milk. Oligosaccharides from fecal samples of exclusively breast-fed infants were extracted and profiled using nanoLC-MS. Intact HMOs were found in the fecal samples, additionally, other oligosaccharides were found corresponding to degraded HMOs and non-HMO based compounds. The latter compounds were fragments of N-glycans released through the cleavage of the linkage to the asparagine residue and through cleavage of the chitobiose core of the N-glycan.

The Veterans Health Administration Medical Facilities dataset includes Veteran Affairs hospitals, Veteran Affairs Residential Rehabilitation Treatment Programs (RRTP), Veteran Affairs Nursing Home Care Units (NHCU), Veteran Affairs Outpatient Clinics (VAOC), Vet Centers, and Veteran Affairs Medical Centers (VAMC). It should not include planned and suspended (non-operational) sites and mobile clinics. These definitions were set by the Veterans Health Administration (VHA) Policy Board in December 1998 and are the basis for defining the category and the additional service types for each VHA service site. These definitions cover sites generally owned by the Department of Veterans Affairs (VA) with the exception of leased and contracted community-based outpatient clinics (CBOCs).1. VA HOSPITAL: an institution (health care site) that is owned, staffed and operated by VA and whose primary function is to provide inpatient services. NOTE: Each geographically unique inpatient division of an integrated facility is counted as a separate hospital.2. VA RESIDENTIAL REHABILITATION TREATMENT PROGRAM (RRTP): provides comprehensive health and social services in a VA facility for eligible veterans who are ambulatory and do not require the level of care provided in nursing homes.3. VA NURSING HOME CARE UNITS (NHCU): provides care to individuals who are not in need of hospital care, but who require nursing care and related medical or psychosocial services in an institutional setting. VA NHCUs are facilities designed to care for patients who require a comprehensive care management system coordinated by an interdisciplinary team. Services provided include nursing, medical, rehabilitative, recreational, dietetic, psychosocial, pharmaceutical, radiological, laboratory, dental and spiritual.4. VA OUTPATIENT CLINICS:a. Community-Based Outpatient Clinic (CBOC): a VA-operated, VA-funded, or VA-reimbursed health care facility or site geographically distinct or separate from a parent medical facility. This term encompasses all types of VA outpatient clinics, except hospital-based, independent and mobile clinics. Satellite, community-based, and outreach clinics have been redefined as CBOCs. Technically, CBOCs fall into four Categories, which are: >(i) VA-owned. A CBOC that is owned and staffed by VA. >(ii) Leased. A CBOC where the space is leased (contracted), but is staffed by VA. NOTE: This includes donated space staffed by VA. >(iii) Contracted. A CBOC where the space and the staff are not VA. This is typically a Healthcare Management Organization (HMO)-type provided where multiple sites can be associated with a single station identifier. >(iv) Not Operational. A CBOC which has been approved by Congress, but has not yet begun operating.b. Hospital-Based Outpatient Clinic: outpatient clinic functions located at a hospital.c. Independent Outpatient Clinic: a full-time, self-contained, freestanding, ambulatory care clinic that has no management, program, or fiscal relationship to a VA medical facility. Primary and specialty health care services are provided in an outpatient setting.5. VET CENTER: Provides professional readjustment counseling, community education, outreach to special populations, brokering of services with community agencies, and access to links between the veteran and VA.6. VA MEDICAL CENTER (VAMC): a medical center is a unique VA site of care providing two or more types of services that reside at a single physical site location. The services provided are the primary service as tracked in the VHA Site Tracking (VAST) (i.e., VA Hospital, Nursing Home, Domiciliary, independent outpatient clinic (IOC), hospital-based outpatient clinic (HBOC), and CBOC). The definition of VA medical center does not include the Vet Centers as an identifying service. This dataset is based upon GFI data received from the National Geospatial-Intelligence Agency (NGA). At the request of NGA, text fields in this dataset have been set to all upper case to facilitate consistent database engine search results. At the request of NGA, all diacritics (e.g., the German umlaut or the Spanish tilde) have been replaced with their closest equivalent English character to facilitate use with database systems that may not support diacritics. The currentness of this dataset is indicated by the [CONTDATE] attribute. Based upon this attribute, the oldest record dates from 09/21/2007 and the newest record dates from 10/15/2007.

BackgroundHuman milk oligosaccharides (HMOs) have important biological functions for a healthy development in early life.ObjectiveThis study aimed to investigate gut maturation effects of an infant formula containing five HMOs (2′-fucosyllactose, 2′,3-di-fucosyllactose, lacto-N-tetraose, 3′-sialyllactose, and 6′-sialyllactose).MethodsIn a multicenter study, healthy infants (7–21 days old) were randomly assigned to a standard cow’s milk-based infant formula (control group, CG); the same formula with 1.5 g/L HMOs (test group 1, TG1); or with 2.5 g/L HMOs (test group 2, TG2). A human milk-fed group (HMG) was enrolled as a reference. Fecal samples collected at baseline (n∼150/formula group; HMG n = 60), age 3 (n∼140/formula group; HMG n = 65) and 6 (n∼115/formula group; HMG n = 60) months were analyzed for microbiome (shotgun metagenomics), metabolism, and biomarkers.ResultsAt both post-baseline visits, weighted UniFrac analysis indicated different microbiota compositions in the two test groups (TGs) compared to CG (P < 0.01) with coordinates closer to that of HMG. The relative abundance of Bifidobacterium longum subsp. infantis (B. infantis) was higher in TGs vs. CG (P < 0.05; except at 6 months: TG2 vs. CG P = 0.083). Bifidobacterium abundance was higher by ∼45% in TGs vs. CG at 6-month approaching HMG. At both post-baseline visits, toxigenic Clostridioides difficile abundance was 75–85% lower in TGs vs. CG (P < 0.05) and comparable with HMG. Fecal pH was significantly lower in TGs vs. CG, and the overall organic acid profile was different in TGs vs. CG, approaching HMG. At 3 months, TGs (vs. CG) had higher secretory immunoglobulin A (sIgA) and lower alpha-1-antitrypsin (P < 0.05). At 6 months, sIgA in TG2 vs. CG remained higher (P < 0.05), and calprotectin was lower in TG1 (P < 0.05) vs. CG.ConclusionInfant formula with a specific blend of five HMOs supports the development of the intestinal immune system and gut barrier function and shifts the gut microbiome closer to that of breastfed infants with higher bifidobacteria, particularly B. infantis, and lower toxigenic Clostridioides difficile.Clinical Trial Registration[https://clinicaltrials.gov/ct2/show/], identifier [NCT03722550].

Pasar Dunia untuk Susu Manusia Oligosakarida (HMO) bernilai $ 125,29 juta pada tahun 2022. Diharapkan tumbuh menjadi $ 332,16 juta pada tahun 2030, dengan tingkat pertumbuhan tahunan majemuk (CAGR) 16,1% dari tahun 2023 hingga 2030. Ukuran pasar, pertumbuhan, bagikan

Pregnancy and postpartum dynamics revealed by millions of lab tests

https://doi.org/10.5061/dryad.1c59zw44t

The dataset contains summary statistics on lab tests from >300K pregnancies in Israel in the period 2003-2020 who are members of "Clalit Healthcare", Israel's largest HMO. It spans 110 different tests at weekly resolution.

Where BMI information was available, the measurements were grouped into three: 15-18.5, 18.5-25, and 25-30. These test results are also included in the ungrouped dataset.

In addition, the dataset contains the same information for 3 common complications: Postpartum hemorrhage (PPH), gestational diabetes mellitus (GDM), and pre-eclampsia. The dataset of these pregnancies is brought at a 4-week resolution due to a lower number of measurements.

See Methods for more details on dataset curation.

Description of the data and fi...